Navigation Links
Fraunhofer in Chile
Date:10/22/2010

This release is available in German.

Professor Alfred Gossner, the CFO of the Fraunhofer-Gesellschaft, announced "The new Fraunhofer Center for Systems Biotechnology in Chile will create links and bring forth innovations for new markets: links between Germany and Chile, between scientific disciplines, between pure research and the demands of private enterprises." Dr. Gossner signed the bilateral agreement with Juan Andrs Fontaine, the Chilean minister for commercial affairs, in the presence of the Chilean President Dr. Sebastin Piera and Chancellor Dr. Angela Merkel in Berlin today. The agreement acknowledges the extensive preparation work on both sides, and clears the way for the new research center to be established in Santiago de Chile.

The Fraunhofer Center for Systems Biotechnology is funded by INNOVAChile, which was created by the governmental economic promotional society CORFO to attract world-class international research institutes to Chile for joint research and development partnerships. Several organizations have been evaluated, but Fraunhofer-Gesellschaft is the first and so far the only one to receive a funding commitment from the Chilean Government. Partners on the Chilean side are: the two iconic universities Pontificia Universidad Catlica de Valparaso (PUCV) and Universidad de Talca, and the private non-profit organization Fundacin Chile. The German partner is the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, headed by Professor Rainer Fischer. The foundation of the Center was actively supported by the German-Chilean Chamber of Industry and Commerce.

The Fraunhofer Center for Systems Biotechnology is the first research center to be launched by the Fraunhofer Chile Research Foundation established on October 4, 2010, and it will work closely with Chilean research organizations and private enterprises. The rese
'/>"/>

Contact: Eckart Bierduempel
eckart.bierduempel@zv.fraunhofer.de
49-224-114-2256
Fraunhofer-Gesellschaft
Source:Eurekalert

Page: 1 2

Related biology news :

1. Environmental scandal in Chile
2. Genome BC, Chile and Norway take another step closer to fully sequencing the salmon genome
3. Genome BC collaborates with Chile and Norway to sequence salmon genome
4. Domestication of Capsicum annuum chile pepper provides insights into crop origin and evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... until they hatched 4.5 years later, according to a ... PLOS ONE by Bruce Robison from Monterey ... have a single reproductive period during their life, where ... eggs until they hatch. Shallow-water octopuses typically care for ... is known about the brooding of deep-sea species. Using ...
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... "Environmental Nanoparticles: Science, Ethics & Policy" on Nov. ... Center in Newark, Del. The registration deadline is ... co-sponsored by UD,s Center for Critical Zone Research ... will include presentations by nationally and internationally recognized ...
... the first critical steps in unraveling the mysteries of ... that afflicts 500,000 people worldwide each year and nearly ... An international team led by Murat Gunel, professor ... and chair of genetics, and a Howard Hughes Medical ...
... Conn. If climate disasters are to be averted, atmospheric carbon ... today, according to a study published in Open Atmospheric ... the United States, the United Kingdom and France. ... a planet similar to that on which civilization developed, an optimum ...
Cached Biology News:Workshop on environmental nanoparticles at UD, Nov. 10-11 2Yale researchers unravel mystery of brain aneurysms 2Revised theory suggests carbon dioxide levels already in danger zone 2
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... When ... has made a lasting impact on both agriculture and weed science around the globe. He ... techniques to benefit farmers. Thousands of students have followed in his footsteps and are now making ... ...
... results of this study will be presented during the ... June 3, 2009 COLUMBIA, Md., May 30 Lead ... from the University of Miami , evaluated whether ... determining rejection or infection in kidney transplant recipients. Patients ...
... and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of a Phase 1 trial presented during an oral ... Annual Meeting. Preliminary results as of April 2009 showed ... addition, OGX-427 demonstrated declines in circulating tumor cells at ...
Cached Biology Technology:Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 2Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 4Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5